Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PLK1 | P53350 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30373303 | 1.00 | NR4A2 (0.69) | NR4A2LMNAALDH1A1SMN1; SMN2PLK1 | |
| Dimethylamine SCHEMBL7778089 | 0.95 | NR4A2 (0.68) | NR4A2LMNAALDH1A1SMN1; SMN2PLK1 | |
| SCHEMBL30421894 | 0.89 | LMNA (0.71) | NR4A2LMNAALDH1A1KDM4E | |
| SCHEMBL1661468 | 0.89 | LMNA (0.71) | NR4A2LMNAALDH1A1KDM4E | |
| SCHEMBL14159256 | 0.88 | NR4A2 (0.71) | NR4A2LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5065671 | 0.87 | CNR2 (0.68) | ALDH1A1PLK1MAPTCREBBP | |
| SCHEMBL1538812 | 0.87 | NR4A2 (0.66) | NR4A2LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13564517 | 0.86 | NR4A2 (0.69) | NR4A2LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL16979075 | 0.85 | KMT2A (0.75) | NR4A2LMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3058391 | 0.85 | NR4A2 (0.68) | NR4A2LMNAALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236590-A1 | A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES | DEB INDUBHUSAN | 2025-07-24 | — | — | US | disclosed |
| EP-4419503-A1 | A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2024-08-28 | — | — | EP | disclosed |
| CN-118265698-A | Process for preparing indole-3-carboxylic acid derivatives | 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) | 2024-06-28 | — | — | CN | disclosed |
| CN-117603120-A | Preparation method and application of indole-3-fluoroketone compound | 平顶山学院 | 2024-02-27 | — | — | CN | disclosed |
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | SPERMATECH AS (NO) | 2023-08-24 | — | — | US | disclosed |
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | SPERMATECH AS (NO) | 2023-08-24 | — | — | US | disclosed |
| WO-2023067628-A1 | A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067628-A1 | A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-04-27 | — | — | WO | disclosed |
| CN-110452235-B | Fluorine-containing isoxazole compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| EP-3713937-A2 | INDOLE COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) MODULATORS | Ariagen, Inc. (US) | 2020-09-30 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-5935954-A | TREATING THE PATIENT SUFFERING FROM PARKINSON'S DISEASE, ALZHIMER'S DISEASE, STROKE AND ISCHEMIA ASSOCIATED WITH STROKE, NEURAL PAROPATHY, SCIATIC CRUSH, SPINAL CORD INJURY OR FACIAL NERVE CRASH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0891331-A1 | N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | Vertex Pharmaceuticals Incorporated (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5717092-A | Compounds with improved multi-drug resistance activity | VERTEX PHARMACEUTICALS INC. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997036869-A1 | N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5552398-A | TREATMENT OF IRRITABLE BOWEL DIARRHEA | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-09-03 | — | — | US | disclosed |
| EP-0603220-A1 | AZABICYCLIC COMPOUNDS AS 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-06-29 | — | — | EP | disclosed |
| EP-0600955-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993005040-A1 | AZABICYCLIC COMPOUNDS AS 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-03-18 | — | — | WO | disclosed |
| WO-1993003725-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | NR5A1, NR1I3, NR5A2 | NR4A2 70/4885LMNA 1688/4885ALDH1A1 1219/4885 |
| US-20250236590-A1 | A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES | IDO1, INMT, IDO2 | NR4A2 4512/4885LMNA 2920/4885ALDH1A1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.